122 related articles for article (PubMed ID: 15009043)
1. CA 125 elevation in breast cancer: a case report and review of the literature.
Leonard GD; Low JA; Berman AW; Swain SM
Breast J; 2004; 10(2):146-9. PubMed ID: 15009043
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of bevacizumab in combination with docetaxel in women with advanced breast cancer.
Ramaswamy B; Shapiro CL
Clin Breast Cancer; 2003 Oct; 4(4):292-4. PubMed ID: 14651775
[No Abstract] [Full Text] [Related]
3. Unknown primary carcinoma, diagnosed as inflammatory breast cancer,and successfully treated with trastuzumab and vinorelbine.
Asakura H; Takashima H; Mitani M; Haba R; Seo R; Yokoe K; Toyama Y; Ohkawa M
Int J Clin Oncol; 2005 Aug; 10(4):285-8. PubMed ID: 16136377
[TBL] [Abstract][Full Text] [Related]
4. A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel.
Kunitomo K; Inoue S; Ichihara F; Kono K; Fujii H; Matsumoto Y; Ooi A
Hum Pathol; 2004 Mar; 35(3):379-81. PubMed ID: 15017597
[TBL] [Abstract][Full Text] [Related]
5. [An advanced metastatic breast cancer patient successfully treated with combination therapy including docetaxel, doxorubicin and cyclophosphamide (TAC) as salvage therapy].
Sato Y; Takayama T; Sagawa T; Sato T; Okamoto K; Takahashi S; Abe S; Iyama S; Murase K; Kato J; Niitsu Y
Gan To Kagaku Ryoho; 2008 Mar; 35(3):471-3. PubMed ID: 18347397
[TBL] [Abstract][Full Text] [Related]
6. Addition of bevacizumab to three docetaxel regimens as adjuvant therapy for early stage breast cancer.
Yardley DA; Hart L; Waterhouse D; Whorf R; Drosick DR; Murphy P; Badarinath S; Daniel BR; Childs BH; Burris H
Breast Cancer Res Treat; 2013 Dec; 142(3):655-65. PubMed ID: 24253810
[TBL] [Abstract][Full Text] [Related]
7. [Subacute cutaneous lupus erythematosus and cancer: two cases and literature review].
Gantzer A; Regnier S; Cosnes A; Ortonne N; Wolkenstein P; Bagot M; Duong TA
Ann Dermatol Venereol; 2011 May; 138(5):409-17. PubMed ID: 21570567
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification.
Saracchini S; Foltran L; Tuccia F; Bassini A; Sulfaro S; Micheli E; Del Conte A; Bertola M; Gion M; Lorenzon M; Tumolo S
Breast; 2013 Dec; 22(6):1101-7. PubMed ID: 24074879
[TBL] [Abstract][Full Text] [Related]
9. Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
Rastogi P; Buyse ME; Swain SM; Jacobs SA; Robidoux A; Liepman MK; Pajon ER; Dy PA; Posada JG; Melnik MK; Piette F; Geyer CE; Mamounas EP; Wolmark N
Clin Breast Cancer; 2011 Aug; 11(4):228-34. PubMed ID: 21684812
[TBL] [Abstract][Full Text] [Related]
10. Serum tumor markers may precede instrumental response to chemotherapy in patients with metastatic cancer.
Massacesi C; Rocchi MB; Marcucci F; Pilone A; Galeazzi M; Bonsignori M
Int J Biol Markers; 2003; 18(4):295-300. PubMed ID: 14756546
[TBL] [Abstract][Full Text] [Related]
11. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.
Miles DW; Chan A; Dirix LY; Cortés J; Pivot X; Tomczak P; Delozier T; Sohn JH; Provencher L; Puglisi F; Harbeck N; Steger GG; Schneeweiss A; Wardley AM; Chlistalla A; Romieu G
J Clin Oncol; 2010 Jul; 28(20):3239-47. PubMed ID: 20498403
[TBL] [Abstract][Full Text] [Related]
12. Use of [(18)F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [(18)F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial.
Coudert B; Pierga JY; Mouret-Reynier MA; Kerrou K; Ferrero JM; Petit T; Kerbrat P; Dupré PF; Bachelot T; Gabelle P; Giard S; Coeffic D; Bougnoux P; Prevost JB; Paintaud G; Thibault G; Hernandez J; Coudert M; Arnould L; Berriolo-Riedinger A
Lancet Oncol; 2014 Dec; 15(13):1493-1502. PubMed ID: 25456368
[TBL] [Abstract][Full Text] [Related]
13. A Locally Advanced Breast Cancer that Achieved pCR with Pertuzumab, Trastuzumab and Docetaxel: Case Report.
Inoue Y; Yamashita N; Tokunaga E; Tanaka K; Ueo H; Saeki H; Oki E; Yamamoto H; Maehara Y
Anticancer Res; 2017 Apr; 37(4):1917-1921. PubMed ID: 28373460
[TBL] [Abstract][Full Text] [Related]
14. HER2-positive breast cancer: update on Breast Cancer International Research Group trials.
Nabholtz JM; Reese DM; Lindsay MA; Riva A
Clin Breast Cancer; 2002 Oct; 3 Suppl 2():S75-9. PubMed ID: 12435291
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer.
Limentani SA; Brufsky AM; Erban JK; Jahanzeb M; Lewis D
J Clin Oncol; 2007 Apr; 25(10):1232-8. PubMed ID: 17296975
[TBL] [Abstract][Full Text] [Related]
16. [A case of paclitaxel and trastuzumab-resistant recurrent breast cancer with liver metastasis responding to S-1].
Nomura T; Sonoo H; Miyake A; Souda M; Yamamoto Y; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Kurebayashi J
Gan To Kagaku Ryoho; 2008 Sep; 35(9):1607-10. PubMed ID: 18799922
[TBL] [Abstract][Full Text] [Related]
17. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer.
Esteva FJ; Valero V; Booser D; Guerra LT; Murray JL; Pusztai L; Cristofanilli M; Arun B; Esmaeli B; Fritsche HA; Sneige N; Smith TL; Hortobagyi GN
J Clin Oncol; 2002 Apr; 20(7):1800-8. PubMed ID: 11919237
[TBL] [Abstract][Full Text] [Related]
19. [A case of effective combination therapy with docetaxel, cyclophosphamide and trastuzumab as primary systemic therapy for locally advanced HER2-positive breast cancer].
Mizuta N; Nishiyama A; Mizuta M; Goto M; Imai A; Umeda Y; Morita M; Sakaguchi K; Konishi E; Taguchi T
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1491-4. PubMed ID: 21918347
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial.
Tedesco KL; Thor AD; Johnson DH; Shyr Y; Blum KA; Goldstein LJ; Gradishar WJ; Nicholson BP; Merkel DE; Murrey D; Edgerton S; Sledge GW
J Clin Oncol; 2004 Mar; 22(6):1071-7. PubMed ID: 15020608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
